Abstract: Malignant melanoma is a kind of highly malignant tumor originated from neural crest melanin ceils, prone to distant metastases, the prognosis of patients with metastatic malignant melanoma is poor. Immunotherapy in recent years gradually becomes the new direction for treating malignant melanoma, a growing number of immune drugs are used in clinical treatment. There has been a revolution in the clinical management of melanoma with the development of multiple antibodies that influence T cell regulatory pathways, including checkpoint inhibition and co-stimulation. In this paper, two monoelonal antibodies （PD-1 and CTLA-4）, and two costimulatory pathways （OX40 and 4-1BB） were reviewed to describe the recent progress for treating melanoma.

Key words: Malignant melanoma, Monoclonal antibody, Costimulatory factor